Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC) (Uro-DNA - GWAS)
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University Hospital, Bordeaux
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Identification of new clear cell Renal Cell Carcinoma (ccRCC) risk loci
Overview
Brief Summary
In the last decade, investigators from the Department of Cancer Epidemiology and Genetics (National Cancer Institute, USA) have conducted genome-wide association (GWAS) studies of renal cell carcinoma.
Dr. Mark PURDUE and Dr. Stephen CAHNOCK (Department of Epidemiology of Cancer and Genetics, NCI) propose to expand their genome-wide association study (Expanded GWAS) by genotyping approximately 10,000 additional cases of kidney cancer patients, in collaboration with US institutions, South-American and European.
This study describes the participation of the French Kidney Cancer Research Network (UroCCR) in the Expanded GWAS research, under the coordination of Professor BERNHARD (Bordeaux University Hospital).
Detailed Description
The aim of the Expanded GWAS study is to better understand the role of common genetic variants in susceptibility to renal cell carcinoma (RCC).
The participation of the French UroCCR network consists in completing the bio-collection of the UroCCR cohort by preserving constitutional DNA and to provide DNA samples to the US NCI team.
This will increase the number of samples for meta-analysis and contribute to better identify clear cell kidney cancer susceptibility loci.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients over 18,
- •Confirmed cases of renal cell carcinoma (any RCC histology) of European or African origin,
- •Patients included in the UroCCR study,
- •Free, informed, written and signed consent by the participant and the investigator (at the latest on the day of inclusion and before any investigation required by the research) for specific blood collection for the purpose of DNA extraction,
- •Programmed or ongoing management for kidney tumor,
- •Constitutional DNA available (whole blood) for selected cases,
- •Affiliated person or beneficiary of a social security scheme.
Exclusion Criteria
- •Patients below 18,
- •Refusal of consent or participation.
Outcomes
Primary Outcomes
Identification of new clear cell Renal Cell Carcinoma (ccRCC) risk loci
Time Frame: Inclusion Visit
From the DNA sample collected at inclusion visit, and the derived Single Nucleotide Polymorphisms (SNPs) genotype data: Association between evaluated genetic variants (SNPs) and renal cell carcinoma will be statistically determined if the p-value is found to be close to or lower than the Genome-wide significance threshold (p \<5\*10-8).
Secondary Outcomes
No secondary outcomes reported